Anne M Muehe1, Ashok J Theruvath1,2, Lillian Lai1, Maryam Aghighi1, Andrew Quon1, Samantha J Holdsworth1, Jia Wang3, Sandra Luna-Fineman4, Neyssa Marina4, Ranjana Advani5, Jarrett Rosenberg1, Heike E Daldrup-Link6,7. 1. Department of Radiology, Pediatric Radiology, Lucile Packard Children's Hospital, Stanford University, 725 Welch Rd, Stanford, CA, 94305-5654, USA. 2. Department of Diagnostic and Interventional Radiology, University Medical Center Mainz, Mainz, Germany. 3. Environmental Health and Safety, Stanford University, Stanford, CA, USA. 4. Department of Pediatrics, Pediatric Hematology/Oncology, Lucile Packard Children's Hospital, Stanford University, Stanford, CA, USA. 5. Department of Medicine, Hematology/Oncology, Stanford Hospital, Stanford University, Stanford, CA, USA. 6. Department of Radiology, Pediatric Radiology, Lucile Packard Children's Hospital, Stanford University, 725 Welch Rd, Stanford, CA, 94305-5654, USA. H.E.Daldrup-Link@stanford.edu. 7. Department of Pediatrics, Pediatric Hematology/Oncology, Lucile Packard Children's Hospital, Stanford University, Stanford, CA, USA. H.E.Daldrup-Link@stanford.edu.
Abstract
PURPOSE: To provide clinically useful gadolinium-free whole-body cancer staging of children and young adults with integrated positron emission tomography/magnetic resonance (PET/MR) imaging in less than 1 h. PROCEDURES: In this prospective clinical trial, 20 children and young adults (11-30 years old, 6 male, 14 female) with solid tumors underwent 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) PET/MR on a 3T PET/MR scanner after intravenous injection of ferumoxytol (5 mg Fe/kg) and [18F]FDG (2-3 MBq/kg). Time needed for patient preparation, PET/MR image acquisition, and data processing was compared before (n = 5) and after (n = 15) time-saving interventions, using a Wilcoxon test. The ferumoxytol-enhanced PET/MR images were compared with clinical standard staging tests regarding radiation exposure and tumor staging results, using Fisher's exact tests. RESULTS: Tailored workflows significantly reduced scan times from 36 to 24 min for head to mid thigh scans (p < 0.001). These streamlined PET/MR scans were obtained with significantly reduced radiation exposure (mean 3.4 mSv) compared to PET/CT with diagnostic CT (mean 13.1 mSv; p = 0.003). Using the iron supplement ferumoxytol "off label" as an MR contrast agent avoided gadolinium chelate administration. The ferumoxytol-enhanced PET/MR scans provided equal or superior tumor staging results compared to clinical standard tests in 17 out of 20 patients. Compared to PET/CT, PET/MR had comparable detection rates for pulmonary nodules with diameters of equal or greater than 5 mm (94 vs. 100 %), yet detected significantly fewer nodules with diameters of less than 5 mm (20 vs 100 %) (p = 0.03). [18F]FDG-avid nodules were detected with slightly higher sensitivity on the PET of the PET/MR compared to the PET of the PET/CT (59 vs 49 %). CONCLUSION: Our streamlined ferumoxytol-enhanced PET/MR protocol provided cancer staging of children and young adults in less than 1 h with equivalent or superior clinical information compared to clinical standard staging tests. The detection of small pulmonary nodules with PET/MR needs to be improved.
PURPOSE: To provide clinically useful gadolinium-free whole-body cancer staging of children and young adults with integrated positron emission tomography/magnetic resonance (PET/MR) imaging in less than 1 h. PROCEDURES: In this prospective clinical trial, 20 children and young adults (11-30 years old, 6 male, 14 female) with solid tumors underwent 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) PET/MR on a 3T PET/MR scanner after intravenous injection of ferumoxytol (5 mg Fe/kg) and [18F]FDG (2-3 MBq/kg). Time needed for patient preparation, PET/MR image acquisition, and data processing was compared before (n = 5) and after (n = 15) time-saving interventions, using a Wilcoxon test. The ferumoxytol-enhanced PET/MR images were compared with clinical standard staging tests regarding radiation exposure and tumor staging results, using Fisher's exact tests. RESULTS: Tailored workflows significantly reduced scan times from 36 to 24 min for head to mid thigh scans (p < 0.001). These streamlined PET/MR scans were obtained with significantly reduced radiation exposure (mean 3.4 mSv) compared to PET/CT with diagnostic CT (mean 13.1 mSv; p = 0.003). Using the iron supplement ferumoxytol "off label" as an MR contrast agent avoided gadolinium chelate administration. The ferumoxytol-enhanced PET/MR scans provided equal or superior tumor staging results compared to clinical standard tests in 17 out of 20 patients. Compared to PET/CT, PET/MR had comparable detection rates for pulmonary nodules with diameters of equal or greater than 5 mm (94 vs. 100 %), yet detected significantly fewer nodules with diameters of less than 5 mm (20 vs 100 %) (p = 0.03). [18F]FDG-avid nodules were detected with slightly higher sensitivity on the PET of the PET/MR compared to the PET of the PET/CT (59 vs 49 %). CONCLUSION: Our streamlined ferumoxytol-enhanced PET/MR protocol provided cancer staging of children and young adults in less than 1 h with equivalent or superior clinical information compared to clinical standard staging tests. The detection of small pulmonary nodules with PET/MR needs to be improved.
Entities:
Keywords:
Cancer; Magnetic resonance imaging; Nanoparticles; Pediatrics; Positron-emission tomography
Authors: Christopher Klenk; Rakhee Gawande; Vy Thao Tran; Jennifer Trinh Leung; Kevin Chi; Daniel Owen; Sandra Luna-Fineman; Kathleen M Sakamoto; Alex McMillan; Andy Quon; Heike E Daldrup-Link Journal: J Nucl Med Date: 2015-10-15 Impact factor: 10.057
Authors: Heike E Daldrup-Link; Ernst J Rummeny; Bettina Ihssen; Joachim Kienast; Thomas M Link Journal: Eur Radiol Date: 2002-02-05 Impact factor: 5.315
Authors: Sergios Gatidis; Holger Schmidt; Brigitte Gücke; Ilja Bezrukov; Guido Seitz; Martin Ebinger; Matthias Reimold; Christina A Pfannenberg; Konstantin Nikolaou; Nina F Schwenzer; Jürgen F Schäfer Journal: Invest Radiol Date: 2016-01 Impact factor: 6.016
Authors: David J Brenner; Richard Doll; Dudley T Goodhead; Eric J Hall; Charles E Land; John B Little; Jay H Lubin; Dale L Preston; R Julian Preston; Jerome S Puskin; Elaine Ron; Rainer K Sachs; Jonathan M Samet; Richard B Setlow; Marco Zaider Journal: Proc Natl Acad Sci U S A Date: 2003-11-10 Impact factor: 11.205
Authors: Ronald Jh Borra; Hoon-Sung Cho; Spencer L Bowen; Ulrike Attenberger; Grae Arabasz; Ciprian Catana; Lee Josephson; Bruce R Rosen; Alexander R Guimaraes; Jacob M Hooker Journal: EJNMMI Phys Date: 2015-02-26
Authors: Ashok J Theruvath; Florian Siedek; Anne M Muehe; Jordi Garcia-Diaz; Julian Kirchner; Ole Martin; Michael P Link; Sheri Spunt; Allison Pribnow; Jarrett Rosenberg; Ken Herrmann; Sergios Gatidis; Jürgen F Schäfer; Michael Moseley; Lale Umutlu; Heike E Daldrup-Link Journal: Radiology Date: 2020-05-05 Impact factor: 11.105
Authors: Anuj Pareek; Anne M Muehe; Ashok J Theruvath; Praveen K Gulaka; Sheri L Spunt; Heike E Daldrup-Link Journal: J Vis Exp Date: 2017-12-19 Impact factor: 1.355
Authors: Jad S Husseini; Bárbara Juarez Amorim; Angel Torrado-Carvajal; Vinay Prabhu; David Groshar; Lale Umutlu; Ken Herrmann; Lina García Cañamaque; José Ramón García Garzón; William E Palmer; Pedram Heidari; Tiffany Ting-Fang Shih; Jacob Sosna; Cristina Matushita; Juliano Cerci; Marcelo Queiroz; Valdair Francisco Muglia; Marcello H Nogueira-Barbosa; Ronald J H Borra; Thomas C Kwee; Andor W J M Glaudemans; Laura Evangelista; Marco Salvatore; Alberto Cuocolo; Andrea Soricelli; Christian Herold; Andrea Laghi; Marius Mayerhoefer; Umar Mahmood; Ciprian Catana; Heike E Daldrup-Link; Bruce Rosen; Onofrio A Catalano Journal: Eur J Nucl Med Mol Imaging Date: 2021-02-22 Impact factor: 9.236
Authors: Heike E Daldrup-Link; Ashok J Theruvath; Ali Rashidi; Michael Iv; Robbie G Majzner; Sheri L Spunt; Stuart Goodman; Michael Moseley Journal: Pediatr Radiol Date: 2021-05-27